Overview

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Eligibility

Inclusion Criteria:

• Subject is ≥ 18 years at the time of signing informed consent;
• Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
• Presence of measurable or evaluable disease;
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
• Contraceptives or other approved avoidance of pregnancy measures

Exclusion Criteria:

• Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
• Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
• Undergone major surgery ≤ 2 weeks prior to starting study drug;
• Evidence of mucosal or internal bleeding;
• Impaired cardiac function or conduction defect;
• Concurrent severe and/or uncontrolled medical conditions